A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

This study aimed to evaluate the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels in adults with a history of atherosclerotic cardiovascular disease or at risk for such events. The results demonstrated that enlicitide significantly lowered LDL cholesterol levels compared to placebo at both 24 and 52 weeks, with no notable difference in adverse events between the groups.